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Objective: To compare the effects of once-daily ciclesonide and twice-daily ﬂuticasone
propionate in patients with moderate persistent asthma.
Methods: Patients aged 12–75 years with moderate bronchial asthma entered a 1–4 week
run-in period. For inclusion into the 12-week, randomized, open-label treatment period,
patients had to have a forced expiratory volume in 1 s (FEV1) of either 60–80% of predicted
or X80% of predicted and a deﬁned use of rescue medication and asthma symptoms,
depending on previous treatment. Patients received ciclesonide 320 mg once daily (ex-
actuator) or ﬂuticasone propionate 200 mg twice daily. Primary efﬁcacy endpoint was
change from baseline in FEV1.
Results: In total, 474 patients were randomized. FEV1 increased signiﬁcantly from
baseline with ciclesonide and ﬂuticasone propionate in the intention-to-treat (ITT) and
per-protocol (PP) analyses (all po0.0001). Treatment difference was 31mL (95%
conﬁdence interval [CI]: 121, 59) in the PP analysis, demonstrating non-inferiority of
ciclesonide. Similar ﬁndings were seen for other measures of lung function. In the ITT
population, asthma symptom scores and rescue medication use decreased with both
treatments (all po0.0001). Improvement in health-related quality of life (HRQoL) from
baseline was signiﬁcantly greater with ciclesonide than ﬂuticasone (p ¼ 0.005; one-sided).
There were no cases of oral candidiasis in patients receiving ciclesonide and nine cases
(3.8%) in those receiving ﬂuticasone propionate (p ¼ 0.002; one-sided).Elsevier Ltd. All rights reserved.
656 4747; fax: +1 418 656 4762.
al.ca (L.-P. Boulet).
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L.-P. Boulet et al.1678Conclusions: Treatment with once-daily ciclesonide and twice-daily ﬂuticasone propio-
nate resulted in similar improvements in lung function in patients with moderate
persistent asthma. Ciclesonide showed signiﬁcant improvements in oral candidiasis and
HRQoL over ﬂuticasone.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Inhaled corticosteroids (ICS) are recommended by national
and international guidelines as ﬁrst-line therapy for patients
with persistent asthma.1–3 They provide local anti-inﬂam-
matory activity and can signiﬁcantly reduce asthma-related
morbidity and mortality.4,5 At standard doses of ICS, adverse
effects are mainly local and can include oral candidiasis and
dysphonia, while long-term use of higher doses may result in
systemic effects,5,6 such as impaired growth in children,
decreased bone mineral density, skin thinning, bruising and
cataracts.5 Studies have indicated, however, that impaired
growth in children at usual doses of ICS is not associated
with detectable effects on ﬁnal adult height.7 Suppression
of hypothalamic–pituitary–adrenal (HPA)-axis function, an
indirect measure of systemic effects, may also occur with
ICS use.6 Although infrequent and often clinically non-
signiﬁcant, such adverse effects (or the fear of them) can
lead to suboptimal compliance and under-use of ICS, which
may result in poor control of asthma.8–10 Therefore,
improved therapies that provide potent airway anti-inﬂam-
matory activity while minimizing the potential for side
effects are welcome.11–13 ICS are usually prescribed at
twice-daily dosing but maintaining clinical efﬁcacy with a
once-daily administration of ICS would simplify individual
asthma treatment and might improve compliance and
health-related quality of life (HRQoL).14,15
Ciclesonide is a novel ICS formulated as a solution and
delivered via a hydroﬂuoroalkane metered-dose inhaler
(HFA-MDI) that provides a large amount of ﬁne particles,
leading to high lung deposition.16 Ciclesonide is adminis-
tered as an inactive prodrug and is converted after
inhalation to its active metabolite, desisobutyryl cicleso-
nide, by airway-speciﬁc esterases.17,18 These properties,
combined with a low oral deposition17,18 and rapid systemic
clearance,17 suggest that ciclesonide may have a low
potential for local and systemic side effects; this has been
supported by placebo-controlled and comparative stu-
dies.19–24 For example, one study showed that daily doses
of ciclesonide up to 1280 mg (ex-actuator) had no clinically
relevant effect on HPA-axis function in contrast to ﬂutica-
sone propionate 440 and 880 mg twice daily, which decreased
plasma cortisol levels.19 Similarly, a study in children
reported no effect of ciclesonide on urinary cortisol
adjusted for creatinine compared with placebo, as well as
no effect on short-term growth as assessed by lower-leg
growth rates.24 In addition, the frequency of local side
effects such as oral candidiasis were reported at the same
rate with ciclesonide and placebo in a pooled analysis based
on 7706 ciclesonide-treated patients.22
Several clinical trials have established the efﬁcacy of
once-daily ciclesonide. In patients with mild-to-moderateasthma, short- and long-term data have shown improved
lung function and reduced asthma symptoms with cicleso-
nide 80–640 mg once daily compared with placebo.23,25,26 In
addition, comparative studies have shown similar efﬁcacy of
ciclesonide with ﬂuticasone propionate in patients with
various degrees of asthma severity.27,28 In this regard,
ciclesonide 160 mg once daily (ex-actuator) and ﬂuticasone
propionate 88 mg twice daily (ex-actuator) showed compar-
able results for improving lung function and asthma
symptoms in patients with mild-to-moderate asthma.27 In
a further study in patients with moderate-to-severe asthma,
both ciclesonide 320 mg twice daily (ex-actuator) and
ﬂuticasone 330 mg twice daily (ex-actuator) maintained
forced expiratory volume in 1 s (FEV1) and improved morning
peak expiratory ﬂow (PEF), asthma symptoms, use of rescue
medication and HRQoL.28 Ciclesonide resulted in fewer local
side effects of oral candidiasis than ﬂuticasone.
We report the ﬁrst clinical trial in patients with moderate
persistent asthma (according to the Global Initiative for
Asthma [GINA] 2002 guidelines) to compare the effects of
once-daily ciclesonide delivered via HFA-MDI and twice-daily
ﬂuticasone propionate delivered via the Diskuss device.
Methods
Patients
Male and female patients aged 12–75 years with a history of
bronchial asthma, as deﬁned by the American Thoracic
Society (ATS),29 of at least 6 months but otherwise in good
health were included in a 1–4 week run-in period prior to
randomization (baseline). Patients had to have been on a
constant dose and type of asthma medication (except rescue
medication) during the 4 weeks prior to the run-in period.
Patients were included in the run-in period if they had
moderate asthma based on GINA 2002 classiﬁcations,30
which take into account current asthma therapy, lung
function (FEV1% of predicted) and the level of asthma
symptoms. Patients were required to have: (1) a FEV1
60–80% of predicted if pretreated with bronchodilators or
non-steroidal ‘controllers’ only; (2) FEV1X80% of predicted
if pretreated with low-dose ICS (ﬂuticasone propionate
p250 mg/day or equivalent); (3) FEV1X80% of predicted and
an asthma symptom score sum p3 (see ‘Efﬁcacy assess-
ments’ section for explanation of scales used) in the
previous 7 days if pretreated with medium-dose ICS
(ﬂuticasone propionate 4250 and p500 mg/day or equiva-
lent); or (4) FEV1X85% of predicted and an asthma symptom
score sum p3 in the previous 7 days if pretreated with low-
dose ICS (ﬂuticasone propionatep250 mg/day or equivalent)
in combination with long-acting beta-agonist (LABA) or
theophylline treatment.
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were previously using bronchodilators or non-steroidal
‘controllers’ without concomitant ICS use had to have an
FEV1 60–80% of predicted and, during the last 7 days of the
run-in period, nocturnal asthma symptoms forp3 nights and
an asthma symptom score sum p20. Patients previously
using ICS had to have an FEV1X80% of predicted. These
patients were required to fulﬁll the following criteria during
the last 7 days of the run-in period: up to one night with
nocturnal asthma symptoms, asthma symptoms more than
once but not daily, and not to have used rescue medication
daily. Reversibility, deﬁned as a change in FEV1X12% of
initial (and at least 200mL) after inhalation of 200–400 mg
salbutamol had to be demonstrated during the run-in
period. If this was not achieved, historical documented
reversibility data up to 12 months or a diurnal PEF
ﬂuctuation of X15% during at least 3 days in the ﬁnal week
of run-in was also accepted as a demonstration of signiﬁcant
reversible airway obstruction.
Patients with concomitant severe diseases, and diseases
contraindicating the use of ICS, or causing impairment of
lung function other than asthma, such as chronic obstructive
pulmonary disease, were excluded. Other exclusion criteria
were: clinically relevant abnormal laboratory values; the
use of systemic steroids in the previous 4 weeks; pregnancy,
breast feeding or not using reliable contraception; or a
current or former smoking status of 10 or more cigarette-
pack years (current or former smokers with o10 cigarette-
pack years were included).
The study was performed in compliance with the Guide-
lines for Good Clinical Practice and the Declaration of
Helsinki in its revised form (Somerset West 1996). The
protocol was approved by the relevant Independent Ethics
Committee or Institutional Review Board for each partici-
pating center. Before recruitment into the study, all patients
gave written informed consent. For adolescents taking part
in the study, their legal representative also gave written
informed consent.Study design
This international study was performed at 59 centers
in Austria, Canada, Germany, Hungary, South Africa
and Spain. The study had a 12-week, randomized,
open-label, parallel-group design and consisted of a run-in
period of 1–4 weeks and a 12-week treatment period.
Treatment during the run-in period was standardized so
that patients previously taking bronchodilators, non-ster-
oidal controllers, concomitant LABA or theophylline stopped
taking these. Patients who had been receiving low-dose
ICS (ﬂuticasone propionate p250 mg/day or equivalent)
continued on the same dose, while those who had received
medium-dose ICS reduced their dose to ﬂuticasone propio-
nate p250 mg/day or equivalent. Salbutamol was used
as rescue medication throughout the study (run-in and
treatment periods) in all groups. After 1 week of run-in,
eligible patients were randomized into the treatment
period—if ineligible, patients were screened again after
2–4 weeks.
At randomization, patients stopped their individual run-in
medication and were assigned to ciclesonide 320 mg oncedaily (ex-actuator; 400 mg ex-valve) in the evening or
ﬂuticasone propionate 200 mg twice daily (total daily dose
400 mg) for 12 weeks. Ciclesonide was administered via a MDI
and ﬂuticasone propionate from a dry powder inhaler
(Diskuss). No other anti-asthma medication was permitted
with the exception of salbutamol (100 mg/puff), which was
used as rescue medication. Randomization was performed
centrally using the Fisher Automated Clinical Trials Service
(FACTS); an automated system assigned each patient to one
of the two treatment groups. Investigators sent a facsimile
form to FACTS and received an immediate automated
response by facsimile instructing them which medication
type to dispense to the patient.Efﬁcacy assessments
FEV1 and forced vital capacity (FVC) were recorded
according to ATS recommendations31 at baseline (time of
randomization) and after 4, 8 and 12 weeks of treatment (or
at study end). Slow vital capacity (SVC) was performed at
baseline and at study end. At each visit, lung function tests
were performed after at least 15min rest and more than 4 h
after rescue medication use. Patients recorded morning and
evening PEF, daytime and nighttime asthma symptom
scores, and use of rescue medication (number of puffs) in
electronic diaries daily for the study duration (during both
run-in and treatment periods). Nighttime asthma symptom
scores were recorded using a 5-point scale: 0 ¼ no asthma
symptoms, slept through the night to 4 ¼ bad night, awake
most of the night because of asthma. Daytime scores were
recorded from 0 ¼ very well, no asthma symptoms to
4 ¼ asthma very bad, unable to carry out daily activities
as usual. Patients were withdrawn from the study at any
time if asthma exacerbation occurred (deﬁned as a
deterioration of asthma that required treatment with oral
steroids).
HRQoL was assessed using the standardized, disease-
speciﬁc Asthma Quality of Life Questionnaire (AQLQ[S]),32,33
which consists of 32 questions in four domains: activity
limitations, symptoms, emotional function and exposure to
environmental stimuli. Patients completed the question-
naire at baseline and after 4 and 12 weeks of treatment. The
net beneﬁt in HRQoL was calculated as the proportion of
patients with an increase of at least 0.5 in the overall
AQLQ(S) score (improvement) minus the proportion of
patients with a decrease of at least 0.5 in the overall
AQLQ(S) score (deterioration).Safety assessments
Safety was assessed by neutral questioning for adverse
events at each study visit. If oropharyngeal events were
reported, a visual inspection of the oropharynx and
conﬁrmation by culture was required. Patients with oro-
pharyngeal events were treated at the discretion of the
investigator and were allowed to remain in the study. In
addition, vital signs (blood pressure and heart rate) were
monitored, and physical examinations and standard clinical
laboratory tests (haematology, biochemistry and urinalysis)
were performed.
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The primary efﬁcacy variable was the change in FEV1 from
baseline to the last visit with a measurement during the
treatment period (intention-to-treat [ITT] population) or to
the last visit with a valid measurement during the treatment
period (per-protocol [PP] population). Secondary efﬁcacy
endpoints included FEV1% predicted, FVC, SVC and number
of asthma exacerbations. For diary measurements, end-
points included change from the last run-in week to the last
treatment week for: morning and evening PEF; daytime,
nighttime and total asthma symptom scores; and the
number of puffs per day of rescue medication. The
percentage of days without asthma symptoms and without
rescue medication was also assessed. Other endpoints were
comparison of overall and individual domain scores from the
AQLQ(S) at each visit with baseline scores.
To achieve a power of 90% for correctly concluding non-
inferiority (a ¼ 0.025, one-sided) for the primary variable,
191 patients were needed for the PP analysis. Allowing for
approximately 25% of patients not qualifying, a sample size
of 510 randomized patients (255 patients in each treatment
group) was required. Tests for non-inferiority of ciclesonide
to ﬂuticasone propionate were based on the PP analysis.
Non-inferiority acceptance limits were set to 200mL for
FEV1 and FVC, 25 L/min for morning and evening PEF and
0.5 for AQLQ(S).
The primary efﬁcacy variable and the secondary variables
based on spirometry, PEF from diaries and AQLQ(S) scores
were analyzed with an analysis of covariance (ANCOVA)
model analogous to that used by Ebbut and Frith.34 The
same model was used for within- and between-treatment
differences. Non-parametric, within-group comparisons of
asthma symptom scores, use of rescue medication and
AQLQ(S) scores were performed using Pratt’s modiﬁed
Wilcoxon’s signed-rank test. Non-parametric between-group
comparisons of asthma symptom scores, use of rescueFigure 1 Flowmedication, AQLQ(S), asthma control (deﬁned as: symp-
tom-free and rescue medication-free days) were performed
using the Mann–Whitney U test. All within- and between-
treatment comparisons of these variables were analyzed by
the ANCOVA model described by Milliken and Johnson.35
Differences in the incidence of local oropharyngeal adverse
events between treatment groups were analyzed using
Fisher’s exact test. For within- and between-treatment
differences, two-sided 95% conﬁdence intervals (CIs) were
provided.Results
Patient characteristics
The study was performed between December 2003 and
September 2004. Of 637 patients enrolled, 474 were
randomized to treatment (234 patients received ciclesonide
320 mg once daily and 240 patients received ﬂuticasone
propionate 200 mg twice daily). One patient in each group
did not receive any medication and, therefore, the ITT
population (all patients who were randomized and took at
least one dose of medication) consisted of 472 patients
(ciclesonide, n ¼ 233; ﬂuticasone propionate, n ¼ 239). Of
these 472 patients, 420 (89.0%) completed the study as
planned (ciclesonide, n ¼ 212; ﬂuticasone propionate,
n ¼ 208) (Fig. 1). The reasons for early discontinuation
included adverse events, lack of compliance, patient
request, other reasons or predeﬁned reasons for disconti-
nuation. The PP population (all patients who completed the
study according to protocol) consisted of 394 patients
(ciclesonide, n ¼ 201; ﬂuticasone propionate, n ¼ 193).
The most frequent protocol violations included: violation
of randomization criteria (13.3%); violation of inclusion
criteria (6.3%); and forbidden concomitant medication (1.5%).
The safety evaluation was based on the ITT population.diagram.
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Table 1 Baseline patient characteristics in the intention-to-treat and per-protocol populations.
Variable ITT (n ¼ 472) PP (n ¼ 394)
Ciclesonide 320 mg
once daily
(n ¼ 233)
Fluticasone
propionate 200 mg
twice daily
(n ¼ 239)
Ciclesonide 320 mg
once daily
(n ¼ 201)
Fluticasone
propionate 200 mg
twice daily
(n ¼ 193)
Age (years) Median (range) 38 (12–73) 40 (12–74) 39 (12–73) 40 (13–74)
Sex
Male n (%) 89 (38) 93 (39) 76 (38) 73 (38)
Female n (%) 144 (62) 146 (61) 125 (62) 120 (62)
Smoking
Non-smoker n (%) 166 (71) 166 (69) 145 (72) 137 (71)
Smoker/ex-
smoker
n (%) 67 (29) 73 (31) 56 (28) 56 (29)
ICS pretreatment
No n (%) 79 (34) 62 (26) 71 (35) 50 (26)
Yes n (%) 154 (66) 177 (74) 130 (65) 143 (74)
Dose Median (range) 500 (200–1000) 500 (100–1000) 500 (200–1000) 500 (100–1000)
FEV1 (mL) Mean7SD 27667724 28437731 27427738 28257718
FEV1% predicted Mean7SD 88.2715.4 90.4713.8 87.9715.9 90.7714.2
Reversibility (%) Mean7SD 19.678.6 19.678.4 19.878.8 20.078.5
ITT ¼ intention to treat; PP ¼ per protocol; ICS ¼ inhaled corticosteroid; FEV1 ¼ forced expiratory volume in 1 s; SD ¼ standard
deviation.
ICS doses expressed as chloroﬂuorocarbon–beclomethasone dipropionate equivalent in mg/day.
Ciclesonide and ﬂuticasone propionate in moderate asthma 1681Baseline and patient characteristics were similar in the
two treatment groups and in the ITT and PP populations
(Table 1). Overall, the majority of patients were Caucasian
and more female than male patients were recruited. Most
patients were being treated with an ICS during the run-in
period, and most had an FEV1X80% of predicted.Figure 2 Change from baseline in forced expiratory volume in
1 s during the 12-week treatment period with either ciclesonide
320 mg once daily or ﬂuticasone propionate 200 mg twice daily
(intention-to-treat analysis). Data are presented as least
squares mean7standard error of the mean. *po0.0001 versus
baseline (randomization at Week 0). CIC ¼ ciclesonide; PM ¼
evening; FP ¼ ﬂuticasone propionate; FEV1 ¼ forced expiratory
volume in 1 s.Lung function
FEV1 increased signiﬁcantly from baseline in both treatment
groups. In patients treated with ciclesonide 320 mg once
daily the increase was 171729mL (least squares [LS]
mean7standard error of the mean [SEM]) (po0.0001) and
in the ﬂuticasone propionate 200 mg twice-daily group the
increase was 186729mL (po0.0001) (ITT population).
Similarly in the PP population, FEV1 increased by
199733mL and 231735mL in the ciclesonide and ﬂutica-
sone propionate groups, respectively (both po0.0001
compared with baseline). The increases in FEV1 were
evident at all post-baseline time points (Fig. 2). Non-
inferiority of ciclesonide was demonstrated; the LS
mean7SEM for the treatment difference was 31746mL
(95% CI: 121, 59; po0.001 one-sided for non-inferiority) in
the PP analysis and 15740mL (95% CI: 93, 63; po0.0001
one-sided for non-inferiority) in the ITT analysis.
Several other measures of lung function showed that both
treatments led to signiﬁcant improvements from baseline
(Table 2). FVC improved signiﬁcantly with both treatments
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Table 2 Changes in lung function measures from baseline after 12 weeks of treatment with either ciclesonide 320 mg once
daily or ﬂuticasone propionate 200 mg twice daily in the intention-to-treat and per-protocol populations.
Variable Change from baseline
ITT population PP population
Ciclesonide
320 mg once
daily
(n ¼ 233)y
p-value Fluticasone
propionate
200 mg twice
daily
(n ¼ 239)y
p-value Ciclesonide
320 mg once
daily
(n ¼ 201)y
p-value Fluticasone
propionate
200mg twice
daily
(n ¼ 193)y
p-value
FEV1 (mL)
Baseline 2805 2805 2775 2775
Change
from
baseline
171729 o0.0001 186729 o0.0001 199733 o0.0001 231735 o0.0001
FEV1 (% predicted)
Baseline 89.26 89.26 89.07 89.07
Change
from
baseline
4.5370.88 o0.0001 5.2170.86 o0.0001 5.1370.98 o0.0001 6.6171.04 o0.0001
FVC (L)
Baseline 3.750 3.750 3.722 3.722
Change
from
baseline
0.18770.033 o0.0001 0.20470.033 o0.0001 0.20070.037 o0.0001 0.23470.039 o0.0001
SVC (L)
Baseline 3.622 3.622 3.634 3.634
Change
from
baseline
0.18470.045 o0.0001 0.15570.044 0.001 0.16570.049 0.001 0.11970.053 0.025
Morning PEF (L/min)
Baseline 398.5 398.5 395.4 395.4
Change
from
baseline
7.973.7 0.034 3.073.7 0.416 8.974.4 0.042 2.974.5 0.514
Evening PEF (L/min)
Baseline 418.6 418.6 411.2 411.2
Change
from
baseline
4.973.8 0.192 8.873.8 0.020 3.674.4 0.416 8.674.7 0.064
ITT ¼ intention to treat; PP ¼ per protocol; FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced vital capacity; SVC ¼ slow vital
capacity; PEF ¼ peak expiratory ﬂow; LS ¼ least squares.
Values are LS mean7standard error of the LS mean.
yValues provided are for the total number of patients in each treatment group in the ITT and PP populations (number of patients for
the primary FEV1 endpoint). Secondary endpoint n numbers may vary. p-values are two-sided for the within-treatment difference (5%
signiﬁcance level).
L.-P. Boulet et al.1682in the ITT and PP populations, with ciclesonide showing a
similar effect to ﬂuticasone propionate (0.03470.051;
95% CI: 0.134, 0.066 in the PP population and
0.01770.045; 95% CI: 0.105, 0.070 in the ITT popula-
tion). Small changes were observed in morning and evening
PEF from electronic diaries; a signiﬁcant increase in morning
PEF was seen in the ciclesonide-treated group (in both the
ITT and PP populations; both po0.050) and a signiﬁcant
decrease in evening PEF was seen in the ﬂuticasonepropionate-treated group (in the ITT population only;
p ¼ 0.020). Non-inferiority was seen for ciclesonide in
morning and evening PEF for both the ITTand PP populations
as the lower limit of the 95% CI in the PP population was
5.7 for morning PEF and 6.8 for evening PEF. FEV1%
predicted and SVC improved signiﬁcantly with both treat-
ments in both populations. There were no signiﬁcant
between-treatment differences in any of these lung function
parameters.
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In the ITT population, daytime and total median asthma
symptom scores were reduced in the ciclesonide group by
0.25 (po0.0001) and 0.29 (po0.0001), and in the ﬂutica-
sone propionate group by 0.29 (po0.0001) and 0.29
(po0.0001), respectively. The median values for nighttime
scores were 0 at baseline and end of study. The PP analysis
yielded similar results. There were no signiﬁcant differences
in asthma symptom scores between the treatment groups.
In the ITT population, the use of rescue medication
decreased by 0.29 puffs/day (po0.0001) in both treatment
groups and there was no signiﬁcant difference between
treatments.
The percentage of days with asthma control (days without
asthma symptoms and without rescue medication) during
the treatment period was achieved at similar rates in the
two groups (85% and 84% in the ciclesonide and ﬂuticasone
propionate groups, respectively, in both the ITT and PP
analyses; Fig. 3). Asthma exacerbations were recorded in
1.3% (3/233) of patients in the ciclesonide group and 2.1%
(5/239) of patients in the ﬂuticasone propionate group
(ITT set).Figure 4 Quality of life net beneﬁt with ciclesonide or
ﬂuticasone propionate (intention-to-treat population). The
net beneﬁt in health-related quality of life was calculated as
the proportion of patients with an increase of at least 0.5 in the
overall AQLQ(S) score (improvement) minus the proportion of
patients with a decrease of at least 0.5 in the overall AQLQ(S)
score (deterioration). Data are presented as percentages.
CIC ¼ ciclesonide; PM ¼ evening; FP ¼ ﬂuticasone propionate;
AQLQ ¼ Asthma Quality of Life Questionnaire.Health-related quality of life
Both ciclesonide and ﬂuticasone propionate signiﬁcantly
improved HRQoL from baseline. In the ITT population, the
mean AQLQ(S) overall score increased from 5.85 at baseline
to 6.14 (po0.0001) after 12 weeks in the ciclesonide group
and from 5.85 to 5.96 (p ¼ 0.030) in the ﬂuticasone
propionate group. The improvement with ciclesonide was
signiﬁcantly greater than with ﬂuticasone propionate (LS
mean7SEM: 0.1870.07; p ¼ 0.005 [one-sided p-value for
superiority]). In the PP population, the between-treatment
difference was not signiﬁcant. In the ITT population, the
HRQoL net beneﬁt was greater with ciclesonide treatment
than with ﬂuticasone propionate treatment (Fig. 4). Similar,Figure 3 Asthma symptom-free days and rescue-medication-free
medians. Error bars represent 68% ranges. CIC ¼ ciclesonide; PM ¼but less pronounced, differences were observed in the PP
population.
Both ciclesonide and ﬂuticasone propionate produced
statistically signiﬁcant increases from baseline in all of the
individual AQLQ(S) domain scores (with the exception of
ﬂuticasone propionate in the ‘activities’ domain in the ITT
analysis). Non-inferiority of ciclesonide to ﬂuticasone
propionate was seen in all domain scores (all po0.0001;
one-sided analysis) in the PP and ITT analyses. The
improvement in the scores for the domains of ‘acti-
vities’ and ‘symptoms’ was signiﬁcantly greater with
ciclesonide versus ﬂuticasone propionate (po0.01; one-
sided analysis, ITT).days (intention-to-treat population). Data are presented as
evening; FP ¼ ﬂuticasone propionate.
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Table 3 Treatment-emergent adverse events reported
by at least 3% of patients in either treatment group
(n ¼ 472).
Adverse event Number (%) patients
Ciclesonide
320 mg once
daily (n ¼ 233)
Fluticasone
propionate 200 mg
twice daily
(n ¼ 239)
Infections
Nasopharyngitis 15 (6.4) 15 (6.3)
Oral candidiasis 0 (0) 9 (3.8)
Respiratory events
Asthma worsening 4 (1.7) 10 (4.2)
Pharyngolaryngeal
pain
8 (3.4) 4 (1.7)
Between-treatment difference: p ¼ 0.002 (one-sided
analysis).
L.-P. Boulet et al.1684Safety
Adverse events
Of 472 patients, 178 (37.7%) experienced at least
one adverse event during the 12-week treatment period.
The overall frequency of adverse events was similar in the
two treatment groups (36.1% in the ciclesonide group and
39.3% in the ﬂuticasone propionate group). The most
frequent adverse event in both treatment groups was
nasopharyngitis (Table 3). In terms of local adverse events,
there were no cases (0%) of oral candidiasis in the
ciclesonide group and nine cases (3.8%) in the ﬂuticasone
propionate group; the difference between the groups
was signiﬁcant (p ¼ 0.002; one-sided analysis). The inci-
dence of dysphonia was similar in both groups (ﬁve and six
cases in the ciclesonide and ﬂuticasone propionate groups,
respectively).
The majority of adverse events in both treatment groups
were mild or moderate in intensity. According to investiga-
tors, nine (3.9%) and 21 (8.8%) adverse events in the
ciclesonide group and ﬂuticasone propionate group, respec-
tively, were likely or deﬁnitely related to the treatment. No
deaths were reported during the study, and one patient
treated with ciclesonide and three patients treated
with ﬂuticasone propionate reported serious adverse
events; none of these were considered to be related
to study medication. Four (1.7%) patients in the cicleso-
nide group and 10 (4.2%) patients in the ﬂuticasone
propionate group discontinued treatment because of ad-
verse events.
Laboratory evaluations and vital signs
Laboratory evaluations showed only minor changes during
the study, with no statistically signiﬁcant differences
between treatment groups. Blood pressure and heart rate
were stable throughout the study period in both treatment
groups, with no clinically relevant changes.Discussion
In this study, the ﬁrst to compare the novel ICS ciclesonide
delivered via MDI with ﬂuticasone propionate delivered via
the Diskuss device, treatment with both ciclesonide 320 mg
once daily and ﬂuticasone propionate 200 mg twice daily
signiﬁcantly improved a number of measures of lung
function, as well as asthma symptom scores and HRQoL in
patients with moderate asthma. In addition, ciclesonide was
shown to be non-inferior to ﬂuticasone propionate for FEV1,
FVC and morning and evening PEF, indicating similar
efﬁcacies of both ICS in this patient population. The
improvements from baseline in FEV1 were signiﬁcant in
both treatment groups despite patients receiving pre-
treatment that resulted in high FEV1 measurements at
baseline (approximately 90% of predicted in both treatment
groups).
The study was conducted in an open-label manner as the
Diskuss device used to deliver ﬂuticasone propionate was
not available as a placebo device. In addition, a placebo arm
was not used in the current study; as a number of previous
placebo-controlled studies with ciclesonide, as well as
studies comparing different doses of ciclesonide, have
indicated its efﬁcacy at improving lung function and
reducing asthma symptoms.23,25,26,36 Therefore, it was
considered unnecessary for patients with moderate asthma
to be withdrawn from treatment to receive placebo in this
study.
The current ﬁndings support those from previous studies
comparing ciclesonide and ﬂuticasone propionate in mild-to-
moderate27 and moderate-to-severe28 asthma. A 12-week,
randomized, double-blind, comparative study of ciclesonide
160 mg once daily with ﬂuticasone propionate 88 mg twice
daily indicated that the two treatments provided similar
improvements in patients with asthma.27 Both treatments
signiﬁcantly improved FEV1, FVC and morning PEF compared
with baseline (all po0.0001). Asthma symptoms and rescue
medication use were also reduced in both groups by a similar
extent.27 In a randomized, open-label, 6-month study
comparing the effects of ciclesonide 320 mg twice daily
(ex-actuator) or ﬂuticasone 330 mg twice daily (ex-actua-
tor), FEV1 was maintained in both treatment groups.
Improvements from baseline in morning PEF, asthma
symptoms, use of rescue medication and AQLQ(S) were
statistically signiﬁcant and comparable between treatment
groups.28
In the current study, while both ciclesonide and ﬂutica-
sone propionate signiﬁcantly improved HRQoL from base-
line, as measured by the AQLQ(S), the improvement in the
ciclesonide group was signiﬁcantly greater than in the
ﬂuticasone propionate group (p ¼ 0.005 [one-sided p-value
for superiority]) in the ITT population. Similarly, the HRQoL
net beneﬁt was greater with ciclesonide than with ﬂutica-
sone propionate. A previously reported study also indicated
signiﬁcant increases in overall AQLQ score for ciclesonide
80, 160 and 320 mg once daily versus placebo (po0.0001) in
patients with mild-to-moderate persistent asthma.23
There was a low and similar frequency of adverse events
reported in both treatment groups, and no unusual or
unexpected events were recorded. In terms of orophar-
yngeal adverse events there was a signiﬁcantly lower
incidence of oral candidiasis recorded in the group of
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A low incidence of local adverse events with ciclesonide has
previously been reported,22,23,26 conﬁrming the favorable
safety and tolerability proﬁle of ciclesonide in the current
study. Such ﬁndings may be due to the low oral deposition of
ciclesonide and minimal conversion to the active metabolite
in the oropharynx.17,18 It is possible that the difference in
the incidence of local adverse events seen between the
treatment groups is a result of the different devices used
(dry powder inhaler versus MDI). However, a recent 6-
month, comparative study in moderate-to-severe asthma
patients comparing the effects of ciclesonide 320 mg twice
daily and ﬂuticasone propionate 330 mg twice daily (both ex-
actuator) administered via MDI devices also showed a
signiﬁcantly lower rate of local oropharyngeal adverse
events (candidiasis and dysphonia combined) with cicleso-
nide (5.1%) versus ﬂuticasone (12.8%; p ¼ 0.001, one-
sided).28 In addition, a previous placebo-controlled study
comparing both devices of ﬂuticasone propionate suggested
no differences between them in terms of adverse events;
the incidence of dysphonia, candidiasis and throat irritation
was similar across all ﬂuticasone propionate treatment
groups.37
In this study, once-daily ciclesonide and twice-daily
ﬂuticasone propionate provided similar improvements in
lung function measures in patients with moderate persistent
asthma in this randomized, open-label, 12-week study. In
addition, both treatments had similar effects on asthma
symptoms, while ciclesonide showed signiﬁcant improve-
ments in the incidence of oral candidiasis and in HRQoL over
ﬂuticasone propionate.
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